This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
Lyrica® has been removed as the preferred brand of pregabalin, generic prescribing is now recommended. Please see the formulary for further information.
Soltel® aerosol inhalation 25micrograms/ metered inhalation has been added into the formulary as the preferred brand of salmeterol inhaler. Soltel® is contraindicated in patients who have peanut and soya allergies. Please see the formulary for further information.
Lecicarbon A suppositories have been added into the formulary for the management of chronic constipation, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.
Ralvo® medicated plasters 700mg have been added as a preferred brand of lidocaine plasters, for the treatment of post-herpetic neuralgia, and should only be used following initiation by the Pain Clinic. Please see the formulary for further information.
Sodium oxybate oral solution 500mg in 1ml has been added into the formulary for the management of narcolepsy with cataplexy in adults aged 19 years and older, in line with specific criteria, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.
Prednisolone 10mg/ml oral solution 30ml bottle has been added into the formulary for patients unable to use standard tablets when total treatment exceeds 150mg. Please see the formulary for further information.
Vensir® XL and Venlablue® XL have been removed as the preferred brands of venlafaxine m/r capsules. Please see the formulary for more information.
Glucodrate® oral powder sachets have been added into the formulary only for patients with short bowel syndrome who are unable to tolerate St Mark's Electrolyte Solution.
NovoRapid PumpCart® insulin aspart 100 units per 1ml, 1.6ml cartridges has been added into the formulary. Please see the formulary for further information.
Diagnostic and monitoring devices for diabetes mellitus: was reviewed and has been refreshed and expanded to include additional information from NICE guideline NG17 (Type 1 diabetes in adults: diagnosis and management). Please see the formulary for further information.
Continence (Chapter 18): has been reviewed following consultation with specialists and the chapter has been refreshed, updated with relevant products, advice, and quick guides. Please see the formulary for further information.
NICE TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction was published in December. The TA recommends treatment with ticagrelor for a maximum of 3 years for patients who have had an MI and who are at high risk of a further event after the initial 12 months of ticagrelor 90mg twice daily or other ADP receptor inhibitor treatment (prasugrel or ticlopidine). The formulary advice has been amended to define those patients at high risk, please see the formulary for further information.
Rosacea guidance: Following the addition of ivermectin to the formulary as a treatment option for rosacea the formulary guidance has been reviewed, with consultation from local specialists. Please see the formulary for up to date guidance.
Braltus® (tiotropium) inhalation powder capsules (£25.50) have been added into the formulary as a less costly alternative to Spiriva® inhalation powder capsules (£33.50), which has been removed. Please see the formulary for further information.
Darifenacin has been added into the formulary as an alternative anti-muscarinic urinary antispasmodic drug. Please see the formulary for further information.
Thick and Easy® and Thick and Easy® Clear have been approved to be added to the formulary. These will be added with some guidance notes on their use, patients should remain on the products recommended and not switched between the two. Also the sachet preparations should not be prescribed as they are significantly more expensive. Please see the formulary for further information.
Pramipexole MR has been added into the formulary alongside the standard release preparation. Pipexus® MR is the preferred brand to be prescribed. Please see the formulary for further information.
Cholurso®has been added into the formulary as the preferred brand of ursodeoxycholic acid. This is only for the 250mg preparation. If a patient requires a higher dose, multiples of the 250mg tablet is less costly. Please see the formulary for further information.
Home > Formulary > Updates > Recent Updates
